GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SCWorx Corp (NAS:WORX) » Definitions » Peter Lynch Fair Value

SCWorx (SCWorx) Peter Lynch Fair Value : $-37.50 (As of Apr. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is SCWorx Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, SCWorx's PEG is 1. SCWorx's 5-Year TTM EBITDA Growth Rate is 25. SCWorx's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.50. Therefore, the Peter Lynch Fair Value for today is $-37.50.

As of today (2024-04-27), SCWorx's share price is $2.34. SCWorx's Peter Lynch fair value is $-37.50. Therefore, SCWorx's Price to Peter Lynch Fair Value Ratio for today is N/A.


The historical rank and industry rank for SCWorx's Peter Lynch Fair Value or its related term are showing as below:



WORX's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 1.315
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


SCWorx Peter Lynch Fair Value Historical Data

The historical data trend for SCWorx's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCWorx Peter Lynch Fair Value Chart

SCWorx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

SCWorx Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SCWorx's Peter Lynch Fair Value

For the Health Information Services subindustry, SCWorx's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCWorx's Price-to-Peter-Lynch-Fair-Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SCWorx's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where SCWorx's Price-to-Peter-Lynch-Fair-Value falls into.



SCWorx Peter Lynch Fair Value Calculation

SCWorx's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *-1.5
=-37.50

SCWorx's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.50.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


SCWorx  (NAS:WORX) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

SCWorx's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=2.34/-37.50
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCWorx Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of SCWorx's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


SCWorx (SCWorx) Business Description

Traded in Other Exchanges
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications and provides the basis for sophisticated data analytics.
Executives
Vincent Michael Matozzo director 412 RICHARD LANE, ORANGE CT 06477
Christopher John Kohler officer: Chief Financial Officer 1149 CANTERBERRY LN, PARKER CO 80138
Steven Wallitt director C/O SCWORX CORP., 590 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10022
John C Ferrara director C/O EDGAR ONLINE, INC., 50 WASHINGTON STREET, NORWALK CT 06854
Steven Ross Horowitz director 4 MELISSA COURT, MONTVILLE NJ 07045
Marc Sanford Schessel director, 10 percent owner, officer: CEO 4 JACOBS LANE, NEW PALTZ NY 12561
Irby Alton F Iii director C/O MCKESSON CORP, ONE POST ST., SAN FRANCISCO CA 94104
Miller Charles Kenneth Iii director 100 METROPLEX, EDISON NJ 08817
Timothy Andrew Hannibal officer: President, COO 590 MADISON AVE, NEW YORK NY 10022
Mark Shefts director 160 SUMMIT AVE, MONTVALE NJ 07645
John C Price other: Former CFO 4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Robert Steven Christie director 34 SAN MARCO STREET, WEST WINDSOR NJ 08550
Ira E. Ritter director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Knuettel Ii Francis director 205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
James Thaddeus Schweikert officer: Chief Operating Officer 7783 SOARING EAGLE CT., CINCINNATI OH 45244